Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCITE: Ranibizumab Dosing Regimens in Wet AMD
NCT00275821Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Primary completion
- Jan 2008
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in exudative macular degeneration (3 arms), sponsored by Novartis. Primary endpoint: Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at 12 months. Started Dec 2005; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00275821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275821.